Our laboratory identified a signature, comprising the actin regulatory protein hMENA, fibronectin, and lymphotoxin β receptor, as unexplored biomarker of TLS-enriched TIME, with prognostic and predictive value for ICB responsiveness in Non-Small Cell Lung Cancer (NSCLC) [34]. The gene discussed is LTBR; the disease is non-small cell lung carcinoma.